Board of Directors

David Szekeres

Executive Chairman

David Szekeres has spent more than 15 years years working in the life sciences and biotechnology industry, and is currently the chief business officer and general counsel at Heron Therapeutics. He previously served as the chief business officer and general counsel of Regulus Therapeutics and the head of mergers and acquisitions at Life Technologies Corporation (recently sold to Thermo Fisher for $16 billion). At Life Technologies, Szekeres led more than 50 transactions valued at over $30 billion, including leading the acquisition of Ion Torrent to expand the company’s genomics business. Prior to his years at Life Technologies, he held positions of increasing responsibility at a number of prestigious law firms, including Latham & Watkins LLP and O’Melveny & Myers LLP, and was an investment banking associate at Robertson Stephens. Szekeres holds a bachelor’s degree from the University of California at Irvine and a J.D. from Duke University.

James Levine

CEO and Director

Bringing two decades of leadership and product commercialization experience, James “Jamie” Levine joined Annai Systems in 2016. Prior to joining Annai Systems, Levine was the CEO of Sapphire Energy and Verenium Corporation – both leading biotech companies that developed products for diverse end-user markets – as well as a managing director in the investment banking department of Goldman Sachs & Co. where he served clients in the healthcare industry. He has an MBA from the Wharton School and a bachelor’s degree from Brandeis University.

Peter Johnson


Peter Johnson was the co-founder and CEO of Agouron Pharmaceuticals, Inc., which pioneered the field of protein structure-based drug design — an engineering approach to drug discovery. Propelled by its successful anti-HIV drug Viracept and a deep R&D pipeline of drugs for other viral diseases and cancer, Agouron became a fully integrated pharmaceutical firm with 1,500 employees and $470 million in revenue before being acquired by Warner-Lambert in 1999 for $2.1 billion, which became a subsidiary of Pfizer in 2000.

Lawrence Ganeshalingam

Founder and Director

An expert in high speed networking systems and semiconductor devices,  Lawrence Ganeshalingam has more than 15 years of experience in engineering and development of hardware and software, including field applications engineering, sales, and business development. Mr. Ganeshalingam was the lead founder and visionary of Annai Systems and remains a key team member. He holds a VLSI design certification at the University of California, Santa Cruz, and a BSEE from San Jose State University.

Tom Casey


With more than two decades of experience, Tom Casey is an experienced executive, entrepreneur, active investor and advisor for leading technology companies. He currently serves as the vice president of platform and infrastructure at Apptio, the independent software-as-a-service leader in technology business management. Before joining Apptio, Casey spent 16 years at Microsoft in various roles including corporate vice president in the business platform division. He was responsible for the strategy and execution of the division’s cloud services initiatives. In addition to serving on Annai’s board of directors, Casey is a partner at 9Mile Labs, a startup accelerator program formed in 2013 and based in Seattle, Washington. He holds a bachelor’s degree in management information systems from the University of Arizona.

Gary Friedman


Gary Friedman was instrumental in co-founding two major public corporations, Pace Membership Warehouse Inc., which was sold to K-Mart, and Agouron Pharmaceuticals Inc., now a subsidiary of Pfizer. He served as the executive vice president of Agouron Pharmaceuticals and as a member of its board of directors. Friedman holds a J.D. and an MBA from the University of California, Berkeley, and a Master of Laws degree from the University of San Diego.